NEW YORK, Nov. 17, 2014 /PRNewswire/ -- For more than a century, the concept of a "magic bullet" to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry.
According to our report, "Global Antibody Drug Conjugate Market Outlook 2018", backed by improved understanding and better technology, the ADC market is anticipated to reach around US$ 3 Billion by 2018. Our report analyzes the market for ADCETRIS and Kadcyla in detail. The market potential of these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. These drugs will take some time in order to capture their entire potential market.
The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glembatumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs.
Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of.
At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
Read the full report: http://www.reportlinker.com/p02048454-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001